Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp

Detalles Bibliográficos
Autores principales: Noorduyn, Stephen G., Johnston, Karissa, Osenenko, Kathy, Sriskandarajah, Niroshan, Gendron, Alain, Mbuagbaw, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645999/
https://www.ncbi.nlm.nih.gov/pubmed/34881326
http://dx.doi.org/10.1183/23120541.00465-2021
_version_ 1784610431167365120
author Noorduyn, Stephen G.
Johnston, Karissa
Osenenko, Kathy
Sriskandarajah, Niroshan
Gendron, Alain
Mbuagbaw, Lawrence
author_facet Noorduyn, Stephen G.
Johnston, Karissa
Osenenko, Kathy
Sriskandarajah, Niroshan
Gendron, Alain
Mbuagbaw, Lawrence
author_sort Noorduyn, Stephen G.
collection PubMed
description Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp
format Online
Article
Text
id pubmed-8645999
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-86459992021-12-07 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Noorduyn, Stephen G. Johnston, Karissa Osenenko, Kathy Sriskandarajah, Niroshan Gendron, Alain Mbuagbaw, Lawrence ERJ Open Res Research Letters Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp European Respiratory Society 2021-12-06 /pmc/articles/PMC8645999/ /pubmed/34881326 http://dx.doi.org/10.1183/23120541.00465-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
spellingShingle Research Letters
Noorduyn, Stephen G.
Johnston, Karissa
Osenenko, Kathy
Sriskandarajah, Niroshan
Gendron, Alain
Mbuagbaw, Lawrence
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title_full Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title_fullStr Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title_full_unstemmed Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title_short Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
title_sort discontinuation of benralizumab in canadian patients with severe eosinophilic asthma
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645999/
https://www.ncbi.nlm.nih.gov/pubmed/34881326
http://dx.doi.org/10.1183/23120541.00465-2021
work_keys_str_mv AT noorduynstepheng discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma
AT johnstonkarissa discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma
AT osenenkokathy discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma
AT sriskandarajahniroshan discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma
AT gendronalain discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma
AT mbuagbawlawrence discontinuationofbenralizumabincanadianpatientswithsevereeosinophilicasthma

Ejemplares similares